Biggest News Aggregation in the World
📰 Lag 3 News

Lag 3 News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Lag 3. Real-time updates on events, politics, business and more.

Dr McKean on the Rationale For Evaluating LAG-3 Inhibitors in Advanced Melanoma

Meredith McKean, MD, MPH, discusses the rationale for investigating the LAG-3 inhibitor fianlimab in combination with cemiplimab-rwlc in patients with advanced melanoma, highlighting the combination's efficacy in both PD-1 inhibitor-exposed and –naïve populations, as well as the combinations its potential clinical significance within the advanced melanoma space.
Meredith Mckean Sarah Cannon Research Institute Skin Cancer Research Program Onclive Tv Lag 3 Pd 1 Inhibitor

Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor

Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor December 29, 2020 16:54 ET | Source: Immutep Limited Immutep Limited Sydney, AUSTRALIA Sydney, AUSTRALIA, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the gr...
United States New South Wales Tim Mccarthy Marc Voigt Immutep Limited United States Patent Trade Mark Office

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science